Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2026 AML Highlights
25 June 2026 | Virtual Meeting
Post-EHA 2026 AML Highlights
Featuring presentations & discussions on selected AML abstracts from the 31st Congress of the European Hematology Association (EHA).
Chair: Naval Daver | Moderators: Emma Searle & Eunice Wang
The Post-EHA 2026 AML Highlights has been supported by Kura Oncology (Silver Sponsor). Supporters have no influence over the production of content.
Session 1: Developments in venetoclax-based combination strategies in AML
Venetoclax and azacitidine for molecular failure intervention as a bridge-to-transplant strategy for NPM1-mutated acute myeloid leukemia: TheGIMEMA AML2521 Phase 2 trial
Chiara Sartor University of Bologna, Bologna, Italy
OPTI-AML: Prospective randomized Phase 2 trial of 28 versus 14 day schedule of venetoclax and azacitidine for 2 cycles in newly diagnosed genomically agnostic acute myeloid leukemia patients ≥60 years
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
A multicenter Phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML)
Jennifer Marvin-Peek The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Triplet therapy with quizartinib, decitabine, and venetoclax in newly diagnosed and relapsed/refractory FLT3-ITD acute myeloid leukemia
Musa Yilmaz University of Texas MD Anderson Cancer Center, Houston, TX, United States
Gilteritinib or ivosidenib in combination with venetoclax-based therapies for FLT3- or IDH1-mutated acute myeloid leukemia
Andrius Žučenka Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
Panel Discussion
Session 2: Latest with immunotherapies and CAR T-cell therapy in AML
Tuscany study of safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in study participants with newly diagnosed AML ineligible for induction chemotherapy
Nikolai Podeltsev Yale School of Medicine, New Haven, CT, United States
Updated findings from the Phase 2 RIVER-81 study of romaciclib (RVU120) combined with venetoclax in acute myeloid leukemia after first-line venetoclax and hypomethylating agent failure
Thomas Cluzeau Central University Hospital of Nice, France
A Phase II randomized study of AK117 versus placebo in combination with venetoclax and azacitidine in previously untreated acute myeloid leukemia patients ineligible for intensive chemotherapy
Huafeng Wang First Affiliated Hospital of Zhejiang University School of Medicine (FAHZU), China
First-in-class switchable allogeneic CAR-T therapy for CD123+ AML – results from the Phase Ia REVSTAR-123 (AVC-201-01) study
Martin Wermke National Center for Tumor Diseases Dresden (NCT/UCC) Early Clinical Trial Unit, Dresden, Germany
Panel Discussion
Session 3: Advances with menin inhibitors in newly-diagnosed AML
Ziftomenib combined with intensive induction (7+3) for newly diagnosed NPM1-M or KMT2A-R acute myeloid leukemia (AML): Long-term results from the KOMET-007 trial
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: Updated Phase 1 results from SNDX-5613-0708
Ibrahim Aldoss City of Hope, Duarte, CA, United States
Panel Discussion
